United States - English - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is an intermediate-acting recombinant human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline a

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin 70/30 is a fixed ratio premix recombinant human insulin formulation indicated to improve glycemic control in adult patients with diabetes mellitus. humulin 70/30 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)], and - in patients who have had hypersensitivity reactions to humulin 70/30 or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly de

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection in cartridge - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - solution for injection in vial - 100 international unit(s)/millilitre - insulins and analogues for injection, fast-acting; insulin (human)

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - solution for injection in cartridge - 100 international unit(s)/millilitre - insulin (human)

Malta - English - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - human insulin (recombinant dna origin) - suspension for injection - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)